Plant phytochemicals as new potential drugs for immune disorders and cancer therapy: Really a promising path?

Journal of the Science of Food and Agriculture

Volumn 92, Issue 8, 2012, Pages 1573-1577

  Chirumbolo, Salvatore ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Cancer prevention; Dietary polyphenols; Flavonoid; Plant phytochemical; Resveratrol; Tea catechins

Indexed keywords

PLANT EXTRACT; POLYPHENOL;

CHEMISTRY; EVOLUTION; HUMAN; IMMUNOPATHOLOGY; NEOPLASM; NOTE; PHYSIOLOGICAL STRESS; PHYTOTHERAPY; PLANT;

BIOLOGICAL EVOLUTION; HUMANS; IMMUNE SYSTEM DISEASES; NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS; POLYPHENOLS; STRESS, PHYSIOLOGICAL;

ANIMALIA; HEXAPODA;

EID: 84859891444     PISSN: 00225142     EISSN: 10970010     Source Type: Journal    
DOI: 10.1002/jsfa.5670     Document Type: Note

References (89)

1. Lattanzio V, Lattanzio VMT and Cardinali A, Role of phenolics in the resistance mechanisms of plants against fungal pathogens and insects, in Phytochemistry: Advances in Research, ed. by Imperato F. 2006, Res Signpost, Kerala, India, pp. 23-67 (2006).
2. Karikas GA, Anticancer and chemopreventing natural products: some biochemical and therapeutic aspects. J Buon 15: 627-638 (2010).
3. Siddiqui IA, Adhami VM, Ahmad N and Mukhtar H, Nanochemoprevention: sustained release of bioactive food components for cancer prevention. Nutr Cancer 62: 883-890 (2010).
4. Nobili S, Landini I, Mazzei T and Mini E, Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev (2011). DOI:10.1002/med.20239.
5. Pitchai D, Manikkam R, Rajendran SR and Pitchai G, Database on pharmacophore analysis of active principles, from medicinal plants. Bioinformation 5: 43-45 (2010).
6. Patwardhan B and Vaidya AD, Natural products drug discovery: accelerating the clinical candidate development using reverse pharmacology approaches. Indian J Exp Biol 48: 220-227 (2010).
7. Lee KW, Bode AM and Dong Z, Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer 11: 211-218 (2011).
8. Chalabi N, Delort L, Le Corre L, Satih S, Bignon YJ and Bernard-Gallon D, Gene signature of breast cancer cell lines treated with lycopene. Pharmacogenomics 7: 663-672 (2006).
9. Huang RS and Ratain MJ, Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 59: 42-55 (2009).
10. Kang NJ, Shin SH, Lee HJ and Lee KW, Polyphenols as small molecular inhibitors of signaling cascades in carcinogenesis. Pharmacol Ther 130: 310-324 (2011).
11. Santangelo C, Varì R, Scazzocchio B, Di Benedetto R, Filesi C and Masella R, Polyphenols, intracellular signalling and inflammation. Ann Ist Super Sanita 43: 394-405 (2007).
12. González-Gallego J, Sánchez-Campos S and Tuñón MJ, Anti-inflammatory properties of dietary flavonoids. Nutr Hosp 22: 287-293 (2007).
13. Guo W, Kong E and Meydani M, Dietary polyphenols, inflammation, and cancer. Nutr Cancer 61: 807-810 (2009).
14. Tuñón MJ, García-Mediavilla MV, Sánchez-Campos S and González-Gallego J, Potential of flavonoids as anti-inflammatory agents: modulation of pro-inflammatory gene expression and signal transduction pathways. Curr Drug Metab 10: 256-271 (2009).
15. Serafini M, Peluso I and Raguzzini A, Flavonoids as anti-inflammatory agents. Proc Nutr Soc 69: 273-278 (2010).
16. Chirumbolo S, The role of quercetin, flavonols and flavones in modulating inflammatory cell function. Inflamm Allergy Drug Targets 9: 263-285 (2010).
17. Williams RJ, Spencer JP and Rice-Evans C, Flavonoids: antioxidants or signalling molecules? Free Radic Biol Med 36: 838-849 (2004).
18. Nam NH, Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem 6: 945-951 (2006).
19. AA.VV, Resveratrol. Monograph, Altern Med Rev 15: 152-158 (2010).
20. Schroecksnadel K, Winkler C, Wirleitner B, Schennach H, Weiss G and Fuchs D, Anti-inflammatory compound resveratrol suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells in vitro. Clin Chem Lab Med 43: 1084-1088 (2005).
21. Chung EY, Kim BH, Hong JT, Lee CK, Ahn B, Nam SY, et al, Resveratrol down-regulates interferon-γ-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation. J Nutr Biochem 22: 902-909 (2011).
22. Lanzilli G, Cottarelli A, Nicotera G, Guida S, Ravagnan G and Fuggetta MP, Anti-inflammatory effect of resveratrol and polydatin by in vitro IL-17 modulation. Inflammation 35: 240-248 (2012).
23. Kostyuk VA, Potapovich AI, Suhan TO, de Luca C and Korkina LG, Antioxidant and signal modulation properties of plant polyphenols in controlling vascular inflammation. Eur J Pharmacol 658: 248-256 (2011).
24. Markus MA and Morris BJ, Resveratrol in prevention and treatment of common clinical conditions of aging. Clin Interv Aging 3: 331-339 (2008).
25. Ungvari Z, Sonntag WE, de Cabo R, Baur JA and Csiszar A, Mitochondrial protection by resveratrol. Exerc Sport Sci Rev 39: 128-132 (2011).
26. Kalantari H and Das DK, Physiological effects of resveratrol. Biofactors 36: 401-406 (2010).
27. Das DK, Mukherjee S and Ray D, Resveratrol and red wine, healthy heart and longevity. Heart Fail Rev 15: 467-477 (2010).
28. Kopp P, Resveratrol, a phytoestrogen found in red wine: a possible explanation for the conundrum of the 'French paradox. Eur J Endocrinol 38: 619-620 (1998).
29. Dudley JI, Lekli I, Mukherjee S, Das M, Bertelli AA and Das DK, Does white wine qualify for French paradox? Comparison of the cardioprotective effects of red and white wines and their constituents: resveratrol, tyrosol, and hydroxytyrosol. J Agric Food Chem 56: 9362-9373 (2008).
30. Wu JM, Wang ZR, Hsieh TC, Bruder JL, Zou JG and Huang YZ, Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine. Int J Mol Med 8: 3-17 (2001).
31. Borriello A, Cucciolla V, Della Ragione F and Galletti P, Dietary polyphenols: focus on resveratrol, a promising agent in the prevention of cardiovascular diseases and control of glucose homeostasis. Nutr Metab Cardiovasc Dis 20: 618-625 (2010).
32. Das M and Das DK, Resveratrol and cardiovascular health. Mol Aspects Med 31: 503-512 (2010).
33. Beaudeux JL, Nivet-Antoine V and Giral P, Resveratrol: a relevant pharmacological approach for the treatment of metabolic syndrome? Curr Opin Clin Nutr Metab Care 13: 729-736 (2010).
34. Kelly G, A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: Part 1. Altern Med Rev 15: 245-263 (2010).
35. Kelly GS, A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: Part 2. Altern Med Rev 15: 313-328 (2010).
36. Lee SM, Yang H, Tartar DM, Gao B, Luo X, Ye SQ, et al, Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. Diabetologia 54: 1136-1146 (2011).
37. Lamont KT, Somers S, Lacerda L, Opie LH and Lecour S, Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection. J Pineal Res 50: 374-380 (2011).
38. Juhasz B, Mukherjee S and Das DK, Hormetic response of resveratrol against cardioprotection. Exp Clin Cardiol 15: e134-138 (2010).
39. Mukherjee S, Dudley JI and Das DK, Dose-dependency of resveratrol in providing health benefits. Dose Response 8: 478-500 (2010).
40. Chirumbolo S, Hormesis, resveratrol and plant derived polyphenols: some comments. Hum Exp Toxicol 30: 2027-2030 (2011).
41. Nakanishi T, Mukai K, Yumoto H, Hirao K, Hosokawa Y and Matsuo T, Anti-inflammatory effect of catechin on cultured human dental pulp cells affected by bacteria-derived factors. Eur J Oral Sci 118: 145-150 (2010).
42. Melgarejo E, Medina MA, Sánchez-Jiménez F and Urdiales JL, Targeting of histamine producing cells by EGCG: a green dart against inflammation? J Physiol Biochem 66: 265-270 (2010).
43. Qin S, Alcorn JF, Craigo JK, Tjoeng C, Tarwater PM, Kolls JK, et al, Epigallocatechin-3-gallate reduces airway inflammation in mice through binding to proinflammatory chemokines and inhibiting inflammatory cell recruitment. J Immunol 186: 3693-3700 (2011).
44. Yoon BI, Ha US, Sohn DW, Lee SJ, Kim HW, Han CH, et al, Anti-inflammatory and antimicrobial effects of nanocatechin in a chronic bacterial prostatitis rat model. J Infect Chemother 17: 189-194 (2011).
45. Ikeda I, Multifunctional effects of green tea catechins on prevention of the metabolic syndrome. Asia Pac J Clin Nutr 17: 273-274 (2008).
46. Thielecke F and Boschmann M, The potential role of green tea catechins in the prevention of the metabolic syndrome: a review. Phytochemistry 70: 11-24 (2009).
47. Sae-Tan S, Grove KA and Lambert JD, Weight control and prevention of metabolic syndrome by green tea. Pharmacol Res 64: 146-154 (2011).
48. Babu PV and Liu D, Green tea catechins and cardiovascular health: an update. Curr Med Chem 15: 1840-1850 (2008).
49. Naito Y and Yoshikawa T, Green tea and heart health. J Cardiovasc Pharmacol 54: 385-390 (2009).
50. Gokulakrisnan A, Vinayagam MM, Rahman LA and Thirunavukkarasu C, Attenuation of cardiac oxidative stress by (-)-epigallocatechin-gallate (EGCG) in CS exposed rats. Biomed Pharmacother (2010). DOI:10.1016/j.biopha.2010.09.025.
51. Tadano N, Du CK, Yumoto F, Morimoto S, Ohta M, Xie MF, et al, Biological actions of green tea catechins on cardiac troponin C. Br J Pharmacol 161: 1034-1043 (2010).
52. Sheng R, Gu ZL, Xie ML, Zhou WX and Guo CY, Epigallocatechin gallate protects H9c2 cardiomyoblasts against hydrogen dioxides-induced apoptosis and telomere attrition. Eur J Pharmacol. 641: 199-206 (2010).
53. Moore RJ, Jackson KG and Minihane AM, Green tea (Camellia sinensis) catechins and vascular function. Br J Nutr 102: 1790-1802 (2009).
54. Yang D, Liu J, Tian C, Zeng Y, Zheng YH, Fang Q, et al, Epigallocatechin gallate inhibits angiotensin II-induced endothelial barrier dysfunction via inhibition of the p38 MAPK/HSP27 pathway. Acta Pharmacol Sin 31: 1401-1406 (2010).
55. Han DW, Lee MH, Kwon BJ, Kim HL, Hyon SH and Park JC, Selective inhibitory effect of epigallocatechin-3-gallate on migration of vascular smooth muscle cells. Molecules 15: 8488-8500 (2010).
56. Babu PV and Liu D, Green tea catechins and cardiovascular health: an update. Curr Med Chem 15: 1840-1850 (2008).
57. González-Gallego J, García-Mediavilla MV, Sánchez-Campos S and Tuñón MJ, Fruit polyphenols, immunity and inflammation. Br J Nutr 104: S15-27 (2010).
58. Perez-Vizcaino F and Duarte J, Flavonols and cardiovascular disease. Mol Aspects Med 31: 478-494 (2010).
59. Hou DX and Kumamoto T, Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling. Antioxid Redox Signal 13: 691-719 (2010).
60. Chong MF, Macdonald R and Lovegrove JA, Fruit polyphenols and CVD risk: a review of human intervention studies. Br J Nutr 104: S28-39 (2010).
61. Pase MP, Grima NA and Sarris J, The effects of dietary and nutrient interventions on arterial stiffness: a systematic review. Am J Clin Nutr 93: 446-454 (2011).
62. Chirumbolo S, Conforti A, Ortolani R, Vella A, Marzotto M and Bellavite P, Stimulus-specific regulation of CD63 and CD203c membrane expression in human basophils by the flavonoid quercetin. Int Immunopharmacol 10: 183-192 (2010).
63. Chirumbolo S, Marzotto M, Conforti A, Vella A, Ortolani R and Bellavite P, Bimodal action of the flavonoid quercetin on basophil function: an investigation of the putative biochemical targets. Clin Mol Allergy 8: 13-24 (2010).
64. Vargas AJ and Burd R, Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. Nutr Rev 68: 418-428 (2010).
65. Jensen JD, Wing GJ and Dellavalle RP, Nutrition and melanoma prevention. Clin Dermatol 28: 644-649 (2010).
66. Shukla Y and Singh R, Resveratrol and cellular mechanisms of cancer prevention. Ann NY Acad Sci 1215: 1-8 (2011).
67. Tang JJ, Fan GJ, Dai F, Ding DJ, Wang Q, Lu DL, et al, Finding more active antioxidants and cancer chemoprevention agents by elongating the conjugated links of resveratrol. Free Radic Biol Med 50: 1447-1457 (2011).
68. Delmas D, Solary E and Latruffe N, Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. Curr Med Chem 18: 1100-1121 (2011).
69. Cal C, Garban H, Jazirehi A, Yeh C, Mizutani Y and Bonavida B, Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr Med Chem Anticancer Agents 3: 77-93 (2003).
70. Kelkel M, Jacob C, Dicato M and Diederich M, Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies. Molecules 15: 7035-7074 (2010).
71. Rahman MA, Amin AR and Shin DM, Chemopreventive potential of natural compounds in head and neck cancer. Nutr Cancer 62: 973-987 (2010).
72. Patel VB, Misra S, Patel BB and Majumdar AP, Colorectal cancer: chemopreventive role of curcumin and resveratrol. Nutr Cancer 62: 958-967 (2010).
73. Shankar S, Nall D, Tang SN, Meeker D, Passarini J, Sharma J, et al, Resveratrol inhibits pancreatic cancer stem cell characteristics in human and kras transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 6: e16530.
74. Singh N, Nigam M, Ranjan V, Zaidi D, Garg VK, Sharma S, et al, Resveratrol as an adjunct therapy in cyclophosphamide-treated MCF-7 cells and breast tumor explants. Cancer Sci 102: 1059-1067 (2011).
75. Ndiaye M, Kumar R and Ahmad N, Resveratrol in cancer management: where are we and where we go from here? Ann NY Acad Sci 1215: 144-149 (2011).
76. Liu X, Zhang DY, Zhang W, Zhao X, Yuan C and Ye F, The effect of green tea extract and EGCG on the signaling network in squamous cell carcinoma. Nutr Cancer 63: 466-475 (2011).
77. Onoda C, Kuribayashi K, Nirasawa S, Tsuji N, Tanaka M, Kobayashi D, et al, (-)-Epigallocatechin-3-gallate induces apoptosis in gastric cancer cell lines by down-regulating survivin expression. Int J Oncol 38: 1403-1408.
78. Tang Y, Zhao DY, Elliott S, Zhao W, Curiel TJ, Beckman BS, et al, Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression. Int J Oncol 31: 705-711 (2007).
79. Kim YW, Bae SM, Lee JM, Namkoong SE, Han SJ, Lee BR, et al, Activity of green tea polyphenols epigallocatechin-3-gallate against ovarian carcinoma cell lines. Cancer Res Treat 36: 315-323 (2004).
80. Johnson JJ, Bailey HH and Mukhtar H, Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine 17: 3-13 (2010).
81. Butt MS and Sultan MT, Green tea: nature's defense against malignancies. Crit Rev Food Sci Nutr 49: 463-473 (2009).
82. Hoensch H, Richling E, Kruis W and Kirch W, Colorectal cancer prevention by flavonoids. Med Klin (Munich) 105: 554-559 (2010).
83. de Souza PL, Russell PJ, Kearsley JH and Howes LG, Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer. Nutr Rev 68: 542-555 (2010).
84. Attoub S, Hassan AH, Vanhoecke B, Iratni R, Takahashi T, Gaben AM, et al, Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur J Pharmacol 651: 18-25 (2011).
85. Pick A, Müller H, Pajeva IK, Weigt M, Mayer R, Haenisch B, et al, Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg Med Chem 19: 2090-2102 (2011).
86. Gupta SC, Kim JH, Prasad S and Aggarwal BB, Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29: 405-434 (2010).
87. Zhao B, Natural antioxidants protect neurons in Alzheimer's disease and Parkinson's disease. Neurochem Res. 34: 630-638 (2009).
88. Calabrese V, Cornelius C, Dinkova-Kostova AT and Calabrese EJ, Vitagenes, cellular stress response, and acetylcarnitine: relevance to hormesis. Biofactors 35: 146-160 (2009).
89. Lampe JW, Interindividual differences in response to plant-based diets: implications for cancer risk. Am J Clin Nutr 89: 1553S-1557S (2009).